Grace Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -3.99%
- Market cap
- $37.97M
- 21.04M shares
- Filings
- 598
FY 2022+50,920.4% FY22 yoy
Q2 2027N/M FY26 yoy
Q2 2027N/M FY26 yoy
Q1 2021derivedN/M FY19 yoy
Q2 2027N/M FY26 yoy
Q2 2027−23.3% FY26 yoy
- $37.97M
- —
- —
- 0.7×
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2022 | 2022-03-31 | $100,000,000 revised | reported | |
| FY 2021 | 2021-03-31 | $196,000 | reported |
Pharmaceutical preparations
Grace Therapeutics, Inc. is the 345th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
BHSTBioharvest Sciences Inc.$34.5M37.0%32.3%$39.7M
GRCEGrace Therapeutics, Inc. (this company)———$38.0M
ATHEAlterity Therapeutics Ltd———$37.9MALDXAldeyra Therapeutics, Inc.———$37.7MSERSerina Therapeutics, Inc.$130.0K132.1%14,755.4%$37.7MAPLMApollomics Inc.Fiscal 2024 figures———$37.6MVERUVeru Inc.———$36.1MTELOTelomir Pharmaceuticals, Inc.———$36.1MANVSAnnovis Bio, Inc.$0.0——$35.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR